검색
Roivant Sciences Ltd
ROIV관심 목록에 추가
33.710USD
+1.500+4.66%
시장 운영 시간 （ET）시세는 15분 지연됩니다
23.92B시가총액
손실P/E TTM
자세한 내용은 Roivant Sciences Ltd 회사
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Roivant Sciences Ltd 정보
종목 코드 ROIV
회사 이름Roivant Sciences Ltd
상장일Dec 03, 2020
CEOVenker (Eric)
직원 수750
유형Ordinary Share
회계 연도 종료Dec 03
주소7Th Floor, 50 Broadway
도시LONDON
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United Kingdom
우편 번호SW1H 0DB
전화4412955950
웹사이트http://roivant.com/
종목 코드 ROIV
상장일Dec 03, 2020
CEOVenker (Eric)
Roivant Sciences Ltd의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.58M
-1.18%
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+0.75%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.46M
-2.36%
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
113.36K
+13.79%
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
101.64K
+0.79%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
93.00K
+0.40%
Mr. Matthew Gline
Mr. Matthew Gline
Chief Executive Officer, Director
Chief Executive Officer, Director
82.26K
--
Mr. Richard Pulik
Mr. Richard Pulik
Chief Financial Officer
Chief Financial Officer
76.72K
-24.71%
Ms. Melissa B. Epperly
Ms. Melissa B. Epperly
Independent Director
Independent Director
68.00
-60575.00%
Dr. Mayukh Sukhatme, M.D.
Dr. Mayukh Sukhatme, M.D.
President, Chief Investment Officer, Director
President, Chief Investment Officer, Director
--
-100.00%
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.58M
-1.18%
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+0.75%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.46M
-2.36%
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
113.36K
+13.79%
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
101.64K
+0.79%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
93.00K
+0.40%
자주 묻는 질문
Roivant Sciences Ltd의 상위 5대 주주는 누구인가요?
Roivant Sciences Ltd의 상위 5대 주주는 다음과 같습니다: Dr. Frank M. Torti, M.D.
Roivant Sciences Ltd(ROIV)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Roivant Sciences Ltd의 주식을 보유한 기관은 총 781곳이며, 이들이 보유한 주식의 총 가치는 약 565.52M로 전체 발행 주식의 79.01%를 차지합니다. 이는 2025Q4 대비 -23023750.00 증가한 수치입니다.
